Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor?

Completed

• Conditions: Anal Carcinoma

• Registration Number: NCT03469596
• Lead Sponsor: Fondation Hôpital Saint-Joseph

Brief Summary

Anal canal cell carcinoma is a very rare cancer but well treated. If the morphological test are well established in the initial evaluation, it's not the case of the follow up evaluation particularly by MRI.About 1/3 of patient decline with metastatic relapse during the follow up of these patients.It appears that clinical regression seen precociously is a predictive factor of survival without relapse. But there 's no study confirming that point.

This context takes us to evaluate if there is a predictive factor in MRI to final clinical result.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-04-01
• Primary Completion: 2017-05-01
• Study Completion: 2017-12-31
• Status Verified: 2018-03
• Study First Submitted: 2018-03-12
• Study First Submitted QC: 2018-03-16
• Study First Posted: 2018-03-19
• Last Update Submitted: 2018-03-21
• Last Update Posted: 2018-03-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 87

Inclusion Criteria

• patient with anal canal cell carcinoma histologically proved
• patient with initial MRI and follow up MRI in Hospital St Joseph's radiology yard.
• patient for whom a radio chemotherapy treatment decision was taken.

Exclusion Criteria

• patients with already metastatic lesions

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Distance with regard to the anal margin	maximum of 6 years after the initial MRI	tumor position
initial tumor size	maximum of 6 years after the initial MRI	Maximal tumoral size in the cranio-caudal plan in cm
presence of nodal status	maximum of 6 years after the initial MRI	presence of nodal status in inguinal region

Trial Locations

Locations (1)

Groupe Hospitalier Paris Saint Joseph; 🇫🇷 Paris, Ile-de-France, France